| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11010726 | Vaccine | 2018 | 9 Pages |
Abstract
Both aTIV and full-dose TIV were well-tolerated and immunogenic in children aged 6-71â¯months. These vaccines may play a role in programmatically suitable strategies to prevent influenza in low-resource settings.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Aldiouma Diallo, John C. Victor, Jodi Feser, Justin R. Ortiz, Niranjan Kanesa-thasan, Moussa Ndiaye, Bou Diarra, Sathie Cheikh, Djibril Diene, Tofene Ndiaye, Assane Ndiaye, Kathryn E. Lafond, Marc-Alain Widdowson, Kathleen M. Neuzil,